| Budget Amount *help |
¥45,900,000 (Direct Cost: ¥45,900,000)
Fiscal Year 2009: ¥9,100,000 (Direct Cost: ¥9,100,000)
Fiscal Year 2008: ¥9,100,000 (Direct Cost: ¥9,100,000)
Fiscal Year 2007: ¥9,100,000 (Direct Cost: ¥9,100,000)
Fiscal Year 2006: ¥9,100,000 (Direct Cost: ¥9,100,000)
Fiscal Year 2005: ¥9,500,000 (Direct Cost: ¥9,500,000)
|
|---|
| Research Abstract |
For the development of more effective and secure target therapy for leukemia, we clarified that mutated FLT3 and KIT, and N-CoR/HDAC3/TBLR1 complex that is recruited by chimera transcription factor PML-RARA are ideal target molecules/complex for therapy. We developed FLT3 inhibitors, FI-700 and KW-2449, and KIT inhibitor, KI-328. For targeting N-CoR/HDAC3/TBLR1 complex we designed a decoy peptide. We also established a laboratory system which can evaluate p-FLT3 or p-STAT5 of leukemia cells using FACS and estimate pharmaco-dynamismly plasma bioassay system.
|
